In vitro, CAR-T cells targeting CD5 successfully kill malignant T cell lines (CCRF-CEM, MOLT-4, and KARPAS-299) and primary T-ALL parent cells (Fig. 2). The gene discussed is CD5; the disease is acute lymphoblastic leukemia.